Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 4, 2005, Pages 1331-1336

  Hiemenz, J ^a,g   Cagnoni, P ^b   Simpson, D ^c   Devine, S ^d,h   Chao, N ^f   Keirns, J ^e   Lau, W ^e   Facklam, D ^e   Buell, D ^e  

^a FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^f DUKE UNIVERSITY   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FLUCONAZOLE; MICAFUNGIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOPHOSPHATEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BONE MARROW TRANSPLANTATION; CHEMOPREVENTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUCONAZOLE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; MYCOSES; NEOPLASMS; PEPTIDES, CYCLIC; STEM CELL TRANSPLANTATION;

EID: 16244367425     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.4.1331-1336.2005     Document Type: Article

References (15)

1. De La Rosa, G. R., R. E. Champlin, and D. P. Kontoyiannis. 2002. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transplant. Infect. Dis. 4:3-9.
2. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., p. 409-416. Marcel Dekker, Inc., New York, N.Y.
3. Grant, S. M., and S. P. Clissold. 1990. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39:877-916.
4. Hatano, K., Y. Morishita, T. Nakai, and F. Ikeda. 2002. Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J. Antibiot. 55:219-222.
5. Ikeda, F., Y. Wakai, S. Matsumoto, K. Maki, E. Watabe, S. Tawara, T. Goto, Y. Watanabe, F. Matsumoto, and S. Kuwahara. 2000. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother. 44:614-618.
6. Marr, K. A., and R. A. Bowden. 1999. Fungal infections in patients undergoing blood and marrow transplantation. Transplant. Infect. Dis. 1:237-246.
7. Matsumoto, S., Y. Wakai, Y. Nakai, K. Hatano, T. Ushitani, F. Ikeda, S. Tawara, T. Goto, F. Matsumoto, and S. Kuwahara. 2000. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob. Agents Chemother. 44:619-621.
8. Mikamo, H., Y. Sato, and T. Tamaya. 2000. In vitro antifungal activity of FK463, a new water soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother. 46:485-487.
9. Nakai, T., J. Uno, K. Otomo, F. Ikeda, S. Tawara, T. Goto, K. Nishimura, and M. Miyaji. 2002. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 48:78-81.
10. Petraitis, V., R. Petraitiene, A. H. Groll, K. Ronssillon, M. Hemmings, C. A. Lyman, T. Sein, J. Bacher, I. Bekersky, and T. J. Walsh. 2002. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 46:1857-1869.
11. Pettengell, K., J. Mynhardt, T. Kluyts, W. Lau, D. Facklam, D. Buell, and the FK463 South African Study Group. 2004. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment. Pharmacol. Ther. 20:475-481.
12. Tawara, S., F. Ikeda, K. Maki, Y. Morishita, K. Otomo, N. Teratani, T. Goto, M. Tomishima, H. Ohki, A. Yamada, K. Kawabata, H. Takasugi, K. Sakane, H. Tanaka, F. Matsumoto, and S. Kuwahara. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44:57-62.
13. Tukey, J. W. 1977. Exploratory data analysis, p. 43-45. Addison-Wesley, Reading, Mass.
14. van Burik, J.-A., V. Ratanatharathorn, D. E. Stepan, C. B. Miller, J. H. Lipton, D. H. Vesole, N. Bunin, D. A. Wall, J. W. Hiemenz, Y. Satoi, J. M. Lee, and T. J. Walsh for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. 2004. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39:1407-1416.
15. Wolff, S., J. Fay, D. Stevens, R. Herzig, B. Pohlman, B. Bolwell, J. Lynch, S. Ericson, C. O. Freytes, F. LeMaistre, R. Collins, L. Pineiro, J. Greer, R. Stein, S. A. Goodman, and S. Dummer. 2000. Fluconazole versus low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant. 25:853-859.